PPARδ agonism for the treatment of obesity and associated disorders: Challenges and opportunities

8Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The prevalence of obesity in the USA and worldwide has reached epidemic proportions during the last two decades. Drugs currently available for the treatment of obesity provide no more than 5% placebo-adjusted weight loss and are associated with undesirable side effects. Peroxisome proliferator-activated receptor (PPAR) modulators offer potential benefits for the treatment of obesity and its associated complications but their development has been complicated by biological, technical, and regulatory challenges. Despite significant challenges, PPAR modulators are attractive targets for the treatment of obesity and could offer a viable alternative to the millions of patients who fail to lose weight following rigorous dieting and exercise protocols. In addition, PPAR modulators have the potential-added benefit of ameliorating the associated comorbidities. Copyright © 2008 Mylène Perreault et al.

Cite

CITATION STYLE

APA

Perreault, M., Erbe, D. V., & Tobin, J. F. (2008). PPARδ agonism for the treatment of obesity and associated disorders: Challenges and opportunities. PPAR Research. https://doi.org/10.1155/2008/125387

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free